Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-MAT: Adjuvant Avelumab in Stage I-III Merkel Cell Carcinoma
NCT04291885Phase 2Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of avelumab in Merkel cell carcinoma (MCC). Started Oct 2020; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04291885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291885.